Detalles de la búsqueda
1.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants.
Naunyn Schmiedebergs Arch Pharmacol
; 397(7): 4737-4745, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38141084
2.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First-in-Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose).
Clin Pharmacol Drug Dev
; 12(2): 202-211, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36065092
3.
Simultaneous estimation of ZY-19489 and its active metabolite ZY-20486 in human plasma using LC-MS/MS, a novel antimalarial compound.
Bioanalysis
; 13(23): 1761-1777, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34779650
4.
Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.
Clin Drug Investig
; 38(1): 57-65, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29022212
5.
Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
Clin Pharmacokinet
; 57(1): 87-102, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28508936
Resultados
1 -
5
de 5
1
Próxima >
>>